Form 4: Veracyte Chief Commercial Officer Reports Routine Stock Withholding for Tax Obligations
Insider Transaction Report
Veracyte, Inc.'s Chief Commercial Officer, John Leite, reported the disposition of 2,900 shares of common stock to cover tax liabilities associated with the vesting of Restricted Stock Units.
Summary
- John Leite, Veracyte, Inc.'s Chief Commercial Officer-CLIA, reported a transaction on June 2, 2025, involving the company's common stock.
- The transaction involved the disposition of 2,900 shares of common stock at a price of $26.74 per share.
- This disposition was not a sale by the reporting person but rather a withholding of shares to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs).
- The shares withheld correspond to RSUs granted on September 1, 2022 (816 shares for 1,606 RSUs), March 6, 2023 (501 shares for 986 RSUs), and March 6, 2024 (1,583 shares for 3,117 RSUs).
- Following this transaction, John Leite beneficially owns 97,349 shares of Veracyte common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common and expected event for executives receiving equity compensation. It does not indicate a change in management's confidence or company performance.
Positives
- The vesting of Restricted Stock Units (RSUs) indicates that the employee has met performance or tenure conditions, which is a positive for employee retention and motivation.
- The transaction is a routine administrative event related to compensation, not a discretionary sale by the insider, which typically does not signal a lack of confidence in the company.
Negatives
- The reporting person's direct beneficial ownership of common stock decreased by 2,900 shares due to tax withholding.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine insider transaction report (Form 4) and does not provide specific insights into broader industry trends or competitive dynamics. It reflects standard compensation practices within the biotechnology or diagnostics industry, where equity-based compensation like RSUs is common.
Stakeholder Impact
- Shareholders: The transaction is a routine administrative event and is unlikely to have a significant direct impact on the share price or shareholder value. It provides transparency into insider holdings.
- Employees: The vesting of RSUs is a positive for the employee (John Leite) as it represents a realization of equity compensation.
Key Dates
| Date | Description |
|---|---|
| 2022-09-01 | Grant date for 1,606 Restricted Stock Units, from which 816 shares were withheld for tax obligations upon vesting. |
| 2023-03-06 | Grant date for 986 Restricted Stock Units, from which 501 shares were withheld for tax obligations upon vesting. |
| 2024-03-06 | Grant date for 3,117 Restricted Stock Units, from which 1,583 shares were withheld for tax obligations upon vesting. |
| 2025-06-02 | Date of earliest transaction reported, involving the disposition of shares for tax withholding. |
| 2025-06-04 | Date the Form 4 was signed by Jonathan Wygant, as attorney-in-fact for John Leite. |
Keywords
Veracyte, VCYT, SEC Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, RSU Vesting, John Leite, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.